Table 4. Predictors of RA development and/or treatment intensification in ACPA-negative undifferentiated arthritis—multivariable analysis.
| RA development | RA development/Treatment intensification | |||||
|---|---|---|---|---|---|---|
| adjOR | 95% CI | P value | adjOR | 95% CI | P value | |
| Large-joint only versus hand-joint only | 0.30 | 0.04 to 2.36 | 0.25 | 1.23 | 0.49 to 3.14 | 0.66 |
| Hand+large-joint versus hand-joint only | 2.68 | 1.29 to 5.57 | 0.008** | 3.32 | 1.77 to 6.24 | <0.001*** |
| CRP >0.5 mg/dL | 2.18 | 0.97 to 4.87 | 0.06 | 2.43 | 1.26 to 4.69 | 0.008** |
| VAS pain, per mm | 1.02 | 1.00 to 1.04 | 0.07 | 1.02 | 1.00 to 1.03 | 0.008** |
**p<0.01 ***p<0.001
ACPA, anticitrullinated protein autoantibodies; adjOR, adjusted OR; CRP, C reactive protein; RA, rheumatoid arthritis; VAS, visual analogue scale.